von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year Journey

ABSTRACT

The correct diagnosis and classification of von Willebrand disease (vWD) is crucial because the presenting biological activity of von Willebrand factor (vWF) determines both the hemorrhagic risk and the subsequent clinical management. A variety of laboratory assays may be employed, not necessarily restricted to assessments of vWF. This article discusses the relative strengths and limitations of various functional or discriminatory vWF assays with a special focus on the vWF:collagen-binding activity (vWF:CBA) assay. This is a functional vWF assay that relies on the property of vWF adhesion to collagen. The vWF:CBA was first described approximately 15 years ago. The journey from that time point has been an interesting one, and the vWF:CBA is now gaining more widespread acceptance. There are now many published studies confirming the superiority of the vWF:CBA over the vWF ristocetin cofactor (vWF:RCof) activity as a functional screening diagnostic test process for vWD. However, both tests may be required in order to appropriately diagnose all forms of vWD. The relationship of these assays with multimer analysis is also discussed. In summary, an optimized vWF:CBA detects primarily high-molecular-weight (HMW) vWF forms and probably only about 30% of the total plasma vWF pool detected by vWF antigen (vWF:Ag). Because these HMW vWF forms are missing in types 2A and 2B vWD, the vWF:CBA is extremely useful in the detection of these qualitative vWD subtypes. In addition, however, concordance of vWF:CBA with vWF:Ag in unison with low vWF levels may alternatively suggest a type 1 vWD, and an absence of both vWF:Ag and vWF:CBA will suggest type 3 vWD. The vWF:CBA is also being investigated in various disease states, as is its usefulness as an effective marker of functional HMW vWF in both desmopressin (DDAVP) and factor-concentrate therapy in vWD.

KEYWORDS

von Willebrand factor - vWF - von Willebrand disease - von Willebrand disorder - vWD - collagen-binding assay - CBA - vWF:CBA - review

REFERENCES

• 1 Sadler J E, Mannucci P M, Berntorp E. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost . 2000;  84 160-174
• 2 Sadler J E, Gralnick H R. Commentary: a new classification for von Willebrand Disease.  Blood . 1994;  84 676-679
• 3 Sadler J E. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost . 1994;  71 520-525
• 4 Ruggeri Z M. Structure and function of von Willebrand Factor.  Thromb Haemost . 1999;  82 576-584
• 5 Guidelines for the diagnosis and management of von Willebrand disease. Prepared by the von Willebrand Working Party of the United Kingdom Haemophilia Centre Directors' Organisation. Haemophilia 1995 3(Suppl 2): 1-8
• 6 Favaloro E J. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.  Blood Rev . 1999;  13 185-204
• 7 Favaloro E J. Appropriate laboratory assessment as a critical facet in the proper diagnosis and sub-classification of von Willebrand's disorder.  Baillieres Clin Haematol . 2001;  14 299-319
• 8 Schneppenheim R, Budde U, Ruggeri Z M. A molecular approach to the classification of congenital von Willebrand Disease.  Baillieres Clin Haematol . 2001;  14 281-298
• 9 Budde U, Drewke E, Mainusch K, Schneppenheim R. Laboratory diagnosis of von Willebrand Disease.  Semin Thromb Haemost . 2002;  28 173-190
• 10 Rodeghiero F, Castamann G, Mannucci P M. Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease.  Blood Rev . 1991;  5 155-161
• 11 Mannucci P M, Cattaneo M. Desmopressin: a nontransfusional treatment of haemophilia and von Willebrand disease.  Haemostasis . 1992;  22 276-282
• 12 Casonato A, Steffan A, Pontara E. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.  Thromb Haemost . 1999;  81 224-228
• 13 Favaloro E J, Smith J, Petinos P, et al. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Scientific Haemostasis Advisory Panel. Laboratory testing, diagnosis and management of von Willebrand's disease: current practice in Australasia.  Am J Clin Pathol . 1999;  112 712-719
• 14 Favaloro E J, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease.  Pathology . 1997;  29 385-391
• 15 Favaloro E J, Smith J, Petinos P, Hertzberg H, Koutts J. on behalf of the RCPA Quality Assurance Program (QAP) in Haematology Haemostasis Scientific Advisory Panel. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey.  Thromb Haemost . 1999;  82 1276-1282
• 16 Favaloro E J, Thom J, Baker R. on behalf of the Australasian Society for Thrombosis and Haemostasis Emerging Technologies Group. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disease: results from the second Australasian laboratory survey.  Blood Coagul Fibrinolysis . 2000;  11 729-738
• 17 Veyradier A, Fressinaud E, Sigaud M, Wolf M, Meyer D. A new automated method for von Willebrand factor antigen measurement using latex particles.  Thromb Haemost . 1999;  81 320-321
• 18 Pittet J L, Barbalat V, Sanvert M. Evaluation of a new automated ELISA test for von Willebrand factor using two monoclonal antibodies.  Blood Coagul Fibrinolysis . 1997;  8 209-215
• 19 Favaloro E J, Aboud M, Arthur C. Possibility of false negative vWD, or potential vWD misclassification, using LIA technology and due to presence of rheumatoid factor.  Am J Hematol . 2000;  66 53-56
• 20 Favaloro E J, Facey D, Grispo L. Laboratory assessment of von Willebrand factor: use of different assays can influence the diagnosis of von Willebrand's disease, dependent on differing sensitivity to sample preparation and differential recognition of high molecular weight vWF forms.  Am J Clin Pathol . 1995;  104 264-271
• 21 Fischer B E, Thomas K B, Dorner F. von Willebrand factor: measuring its antigen of function?.  <~>Correlation between the level of antigen, activity, and multimer size using various detection systems. Thromb Res . 1998;  91 39-43
• 22 Mannuci P M, Abildgaard C F, Gralnick H R. Multicenter comparison of von Willebrand factor multimer sizing techniques. Report of the FVIII and von Willebrand factor subcommittee.  Thromb Haemost . 1985;  54 873-877
• 23 Baillod P, Affolter B, Kurt G H, Pflugshaupt R. Multimeric analysis of von Willebrand factor by vertical sodium docecyl sulphate agarose gel electrophoresis, vacuum blotting technology and sensitive visualisation by alkaline phosphatase anti-alkaline phosphatase complex.  Thromb Res . 1992;  66 745-755
• 24 Howard M A, Firkin B G. Ristocetin. A new tool in the investigation of platelet aggregation.  Thrombosis et Diathesis Haemorrhagica . 1971;  26 362-365
• 25 Weiss H J, Hoyer L W, Rickles F R, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation.  J Clin Invest . 1973;  52 2708-2717
• 26 MacFarlane D E, Stibbe J, Kirby E P. A method for assaying von Willebrand's factor (ristocetin cofactor).  Thrombosis et Diathesis Haemorrhagica . 1975;  34 306-308
• 27 Favaloro E J, Mehrabani P A, Koutts J. Laboratory assessment of von Willebrand factor: altered interpretation of laboratory data, and altered diagnosis of von Willebrand's disease, as influenced by the use of different vWF assays and assay conditions.  Clin Appl Thromb Hemost . 1997;  3 110-118
• 28 Goodall A H, Jarvis J, Chand S. An immunoradiometric assay for human factor VIII von Willebrand factor (VIII:vWF) using a monoclonal antibody base that defines a functional epitope.  Br J Haematol . 1985;  59 565-577
• 29 Chand S, McCraw A, Hutton R, Tuddenham E GD, Goodall A H. A two-site, monoclonal antibody based immunoassay for von Willebrand factor. Demonstration that vWF function resides in a conformational epitope.  Thromb Haemost . 1986;  55 318-324
• 30 Murdock P J, Woodhams B J, Mathews K B, Pasi K J, Goodall A H. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use.  Thromb Haemost . 1997;  78 1272-1277
• 31 Vanhoorelbeke K, Cauwenberghs N, Vauterin S. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor.  Thromb Haemost . 2000;  83 107-113
• 32 Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G, Vauterin S, Deckmyn H. A reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.  Semin Haemost Thromb . 2002;  28 161-166
• 33 Preston F E. Assays for von Willebrand factor functional activity: a UK NEQAS Survey.  Thromb Haemost (Letter) . 1998;  80 863
• 34 Favaloro E J. Collagen binding assay for von Willebrand factor (vWF:CBA): detection of von Willebrand's disease (vWD), and discrimination of vWD subtypes, depends on collagen source.  Thromb Haemost . 2000;  83 127-135
• 35 Favaloro E J, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrand's disease (vWD) subtypes: direct comparison of von Willebrand factor:collagen binding activity/assay (vWF:CBA) with monoclonal antibody (MAB) based ELISA vWF-detection systems.  Thromb Haemost . 2000;  84 541-547
• 36 Favaloro E J. Discrimination of von Willebrand's disease (vWD) subtypes: direct comparison of commercial ELISA-based options used to detect qualitative von Willebrand factor (vWF) defects.  Am J Clin Pathol . 2000;  114 608-618
• 37 Federici A B, Canianci M T, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalised to antigen levels for a rapid diagnosis of type 2 von Willebrand disease.  Thromb Haemost . 2000;  84 1127-1128
• 38 Brown J E, Bosak J O. An ELISA test for the binding of von Willebrand antigen to collagen.  Thromb Res . 1986;  43 303-311
• 39 Favaloro E J, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease.  Blood Coagul Fibrinolysis . 1991;  2 285-291
• 40 Favaloro E J, Grispo L, Dinale A, Berndt M, Koutts J. von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor.  Pathology . 1993;  25 152-158
• 41 Facey D A, Favaloro E J, Maxwell E, Baker R, Hertzberg M S. Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: phenotype and genotype correlations.  Am J Hematol . 2000;  63 197-199
• 42 Facey D A, Favaloro E J, Koutts J, Berndt M C, Hertzberg M. Identification and characterisation of a novel mutation in von Willebrand factor causing a type 2B von Willebrand's disease.  Br J Haematol . 1999;  105 538-541
• 43 Siekmann J, Turecek P L, Fischer B E. Characterisation of plasma-derived and recombinant human vWF by improved collagen binding assays.  Thromb Haemost . 1995;  73 1160-1166
• 44 Casonato A, Pontara E, Bertomoro A. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers.  J Lab Clin Med . 1997;  129 251-259
• 45 Ramasamy I, Farrugia A, Tran E, Anastasius V, Charnock A. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.  Biologicals . 1998;  26 155-166
• 46 Dean J A, Blanchette V S, Carcao M D. von Willebrand disease in a paediatric-based population: comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.  Thromb Haemost . 2000;  84 401-409
• 47 Siekmann J, Turecek P L, Schwarz H P. The determination of von Willebrand factor activity by collagen binding assay.  Hemophilia . 1998;  4(Suppl 3) 15-24
• 48 Fischer B E, Kramer G, Mitterer A. Effect of multimerisation of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.  Thromb Res . 1996;  84 55-66
• 49 Fischer B E. Recombinant von Willebrand factor: potential therapeutic use.  J Thromb Thrombolysis . 1999;  8 197-205
• 50 Fischer B E, Thomas K B, Dorner F. Collagen covalently immobilized onto plastic surfaces simplifies measurement of von Willebrand factor-collagen binding activity.  Ann Hematol . 1998;  76 159-166
• 51 Fischer B E, Schlokat U, Reiter M, Mundt W, Dorner F. Biochemical and functional characterization of recombinant von Willebrand factor produced on a large scale.  Cell Mol Life Sci . 1997;  53 943-950
• 52 Turecek P L, Siekmann J, Schwarz H P. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.  Semin Thromb Hemost . 2002;  28 149-160
• 53 Neugebauer B M, Goy C, Budek I, Seitz R. Comparison of two von Willebrand factor collagen-binding assays with different affinities for low, medium, and high multimers of von Willebrand factor.  Semin Thromb Hemost . 2002;  28 139-148
• 54 Kempfer A C, Silaf M R, Farias C E. Binding of von Willebrand factor to collagen by flow cytometry.  Am J Clin Pathol . 1999;  111 418-423
• 55 van Genderen J P, Prins F J, Lucas I S. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count.  Br J Haematol . 1997;  99 832-836
• 56 van Genderen J P, Budde U, Michiels J J, van Strik R, van Vliet H H. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.  Br J Haematol . 1996;  93 962-965
• 57 Huizinga E G, Martijn van der Plas R, Kroon J, Sixma J J, Gros P. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding.  Structure . 1997;  5 1147-1156
• 58 Stieger J, de la Cuadra J, Furlan M, Beck E A. A new test for evaluating the von Willebrand factor: collagen-induced agglutination of fixed thrombocytes.  Schweiz Med Wochenschr . 1986;  116 1489-1490
• 59 Aihara M, Kudo I, Ishigaki H. Two affinity immunoelectrophoretic methods for studying collagen interaction with von Willebrand factor antigen.  Tohoku J Exp Med . 1987;  153 169-177
• 60 Duggan M J, DiMichele D M, Christian M J, Fink L M, Hathaway W E. Collagen-binding of von Willebrand's factor antigen in the classification of von Willebrand's disease.  Am J Clin Pathol . 1987;  88 97-102
• 61 Fauvel-Lafeve F, Legrand Y J. Binding of plasma von Willebrand factor by arterial microfibrils.  Thromb Haemost . 1990;  64 145-149
• 62 Inbal A, Loscalzo J. Glycocalicin binding to von Willebrand factor adsorbed onto collagen-coated or polystyrene surfaces.  Thromb Res . 1989;  56 347-357
• 63 Favaloro E J. Sulfatide-binding assay for von Willebrand factor: detection of von Willebrand's disease without discrimination of vWD subtypes.  Thromb Res . 2000;  98 213-219
• 64 Favaloro E J. Utility of the PFA-100^℗ for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations.  Haemophilia . 2001;  7 170-179
• 65 Favaloro E J, Kershaw G, Bukuya M, Hertzberg M, Koutts J. Laboratory diagnosis of von Willebrand disorder (vWD) and monitoring of DDAVP therapy: efficacy of the PFA-100^(c) and vWF:CBA as combined diagnostic strategies.  Haemophilia . 2001;  7 180-189
• 66 Lawrie A S, Harrison P, Armstrong A L. Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates.  Br J Haematol . 1989;  73 100-104
• 67 Oates A, Polmear E, Herrington R. von Willebrand factor characterization of a severe dry-heat treated factor VIII concentrate, AHF (high purity).  Thromb Res . 1992;  65 389-399
• 68 Burnouf-Radosevich M, Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate.  Vox Sang . 1992;  62 1-11
• 69 Lusher J M. Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP-a survey of European physicians.  Haemophilia . 1998;  4(Suppl 3) 11-14
• 70 Chang P, Aronson D L. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities.  Thromb Haemost . 1997;  78 930-933
• 71 Barington K A, Kaersgaard P. A very-high-purity von Willebrand factor preparation containing high-molecular-weight multimers.  Vox Sang . 1999;  76 85-89
• 72 Hubbard A R, Rigsby P, Barrowcliffe T W. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).  Thromb Haemost . 2001;  4 634-638
• 73 Favaloro E J, Dean M, Grispo L, Exner T, Koutts J. von Willebrand's disease: use of collagen binding assay provides potential improvement to laboratory monitoring of desmopressin (DDAVP) therapy.  Am J Hematol . 1994;  45 205-211
• 74 Mauz-Korholz C, Budde U, Korholz D, Gobel U. DDAVP treatment in a child with von Willebrand disease type 2M.  Eur J Pediatr . 1999;  158(Suppl 3) S174-176
• 75 Casonato A, Pontara E, Bertomoro A. von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin cofactor activity?.  Br J Haematol . 2001;  112 578-583
• 76 Johnstone I B. Desmopressin enhances the binding of plasma von Willebrand factor to collagen in plasmas from normal dogs and dogs with type I von Willebrand's disease.  Can Vet J . 1999;  40 645-648
• 77 Johnstone I B. Plasma von Willebrand factor-collagen binding activity in normal dogs and in dogs with von Willebrand's disease.  J Vet Diagn Invest . 1999;  11 308-313
• 78 van Genderen J P, Leenknegt H, Michiels J J, Budde U. Acquired von Willebrand disease in myeloproliferative disorders.  Leuk Lymphoma . 1996;  22(Suppl 1) 79-82
• 79 van Genderen J P, Vink T, Michiels J J. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.  Blood . 1994;  84 3378-3384
• 80 Rasko J EJ, North K, Favaloro E J, Grispo L, Berndt M C. Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1.  Br J Haematol . 1995;  89 582-588
• 81 Niesvizky R, Calandri C, Patel N D. von Willebrand factor binding to collagen in patients with end-stage renal disease.  J Lab Clin Med . 1994;  123 137-142
• 82 Gerritsen H E, Turecek P L, Schwarz H P, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP).  Thromb Haemost . 1999;  82 1386-1389
• 83 Furlan M, Lämmle B. Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura.  Semin Thromb Haemost . 2002;  28 167-172
• 84 Aronson D L, Krizek D M, Rick M E. A rapid assay for the vWF protease.  Thromb Haemost . 2000;  85 184-185
• 85 Xie L, Chesterman C N, Hogg P J. Reduction of von Willebrand factor by endothelial cells.  Thromb Haemost . 2000;  84 506-513
• 86 Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti M L. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion.  Thromb Res . 1999;  96 213-217
• 87 Fressinaud E, Veyradier A, Sigaud M. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates.  Br J Haematol . 1999;  106 777-783
• 88 Kertzscher F, Muller A E, Lenk H. Analysis of von Willebrand factor in platelets of patients with various forms of von Willebrand disease: is there a clinical relevance?.  Eur J Paediatr . 1999;  158(Suppl 3) S177-S179
• 89 Perrin E J, Ray M J, Hawson G A. The role of von Willebrand factor in haemostasis and blood loss during and after cardiopulmonary bypass surgery.  Blood Coagul Fibrinolysis . 1995;  6 650-658
• 90 Thomas K B, Sutor A H, Altinkaya N. von Willebrand factor-collagen binding activity is increased in newborns and infants.  Acta Paediatr . 1995;  84 697-699
• 91 Zieger B, Budde U, Jessat U. New families with von Willebrand disease type 2M (Vicenza).  Thromb Res . 1997;  87 57-64
• 92 Hillery C A, Mancuso D J, Evan Sadler J. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin - but not botrocetin-mediated binding of von Willebrand factor to platelets.  Blood . 1998;  91 1572-1581
• 93 Favaloro E J, Mehrabani P A. Laboratory assessment of von Willebrand factor: differential influence of prolonged ambient temperature specimen storage on assay results.  Haemophilia . 1996;  2 218-223
• 94 Farrugia A, Street A, Douglas S. Stabilization of von Willebrand factor in banked blood by leukocyte depletion.  Transfus Med . 1993;  3 51-57

1 *Since writing this review, we have published in more detail on this topic (Favaloro EJ, Nair SC, Forsyth CJ. Collection and transport of samples for laboratory testing in von Willebrand's disease (vWD): time for a reappraisal? Thromb Haemost 2001;86:1589-1590)